Abstract
Objectives To determine the prevalence of antibodies to SARS-CoV-2 and the incidence of seroconversion in the first month of follow-up among interns, residents, and medical doctors attending patients at a University Hospital, to explore for associations of seroprevalence and seroconversion with risk factors and symptoms compatible with COVID-19, and to explore the concordance of CLA, LFA, and ELFA.
Design or methods We conducted a cross-sectional and a prospective study among medical doctors and medical trainees at Hospital Universitario San Ignacio in Bogota (Colombia) during June, July, and August to assess seroprevalence and seroconversion rates in this population was performed using CLA IgG for SARS-CoV-2. LFA IgG and IgM and ELFA IgM were also determined to explore concordance with CLA IgG.
Results At baseline, 8 (2.28% 95%CI 1.16-4.43%) individuals were IgG positive for SARS-CoV-2 by CLA. At the end of the study, 21 (5.98% 95%CI 3.94-8.97%) individuals seroconverted by CLA IgG. In all, 29 individuals had IgG by CLA and of these 11 (3.13% 95%CI 1.76-5.52%) were asymptomatic. No associations with risk factors for infection were identified. CLA had moderate concordance with LFA IgG and ELFA, but minimal with LFA IgM.
Conclusions Our report is one of the first in Latina America on seroprevalence and seroconversion rates in medical healthcare workers. It emphasizes the importance of avoiding focusing only on symptomatic individuals to screen this population for SARS-CoV-2 infection, since of all individuals that have evidence of previous infection many (37.93%) may be pre-symptomatic or asymptomatic and may contribute to infection/disease spread.
Highlights
Latin America was one of the most severely compromised regions of the world during the SARS-CoV-2 pandemic, between June and August 2020.
Healthcare workers are at increased risk for COVID-19 and studies of seroprevalence and seroconversion rates in these subjects have not been published in the area.
We conducted a cross-sectional and prospective study of medical doctors and medical trainees in a University Hosptial during June, July, and August 2020 to assess seroprevalence and seroconversion rates of SARS-CoV-2 in this population, using a Chemiluminescent assay (CLA).
At baseline, 8 (2.28% 95%CI 1.16-4.43%) individuals were IgG positive for SARS-CoV-2 by CLA. At the end of the study, 21 (5.98% 95%CI 3.94-8.97%) individuals had seroconverted by CLA IgG.
In all, 29 (8.26% 95%CI 5.81-11.61%) individuals had IgG for SARS-CoV-2 by CLA and of these 11 (3.13% 95%CI 1.76-5.52%) were asymptomatic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, and Fundacion Bolivar Davivienda.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our project complied with the legal and ethical guidelines contemplated in the Declaration of Helsinki of the World Medical Association, Fortaleza, Brazil, 2013. Likewise, it adheres to the ethical considerations outlined in articles 15 and 16 of Resolution No. 008430 of 1993 of the Ministry of Health and in Law 84 of 1989. The study and the informed consent form were approved by the ethics committee of School of Medicine of the Pontificia Universidad Javeriana and HUSI.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All study data is available upon request
